TGFBR2 and diabetic kidney disease: This binding inhibits the ubiquitin‐proteasome‐mediated degradation of TGFBR2 and increases TGFβ1 levels, thereby enhancing the profibrotic effects of the TGFβ1 signaling pathway and promoting the progression of renal fibrosis and DKD.